<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01699555</url>
  </required_header>
  <id_info>
    <org_study_id>GNC-001</org_study_id>
    <nct_id>NCT01699555</nct_id>
  </id_info>
  <brief_title>First-in-Human Study With GNbAC1 in Healthy Volunteers</brief_title>
  <official_title>Randomized Placebo-Controlled First-in-Human Study With GNbAC1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeNeuro Innovation SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GeNeuro SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of single ascending doses&#xD;
      of GNbAC1 in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scientific research has shown that the expression of genes of a virus which is integrated in&#xD;
      the Human genetic material, the Multiple Sclerosis associated RetroVirus (MSRV) could play a&#xD;
      critical role in the causation of multiple sclerosis. GNbAC1 is an experimental medication,&#xD;
      which neutralizes (i.e. inactivates) a protein of MSRV that might contribute to the&#xD;
      development or deterioration of multiple sclerosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of reported adverse events for healthy male subjects receiving single ascending doses of GNbAC1.</measure>
    <time_frame>64 days</time_frame>
    <description>the number of adverse events along with the results of physical examinations, ECG and clinical laboratory tests will be used to determine the safety profile of GNbAC1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics (PK) characteristics following administration of single ascending doses of GNbAC1 in healthy male subjects</measure>
    <time_frame>64 days</time_frame>
    <description>the following parameters will be determined: serum concentrations of GNbAC1 and the derived PK parameters AUC0-inf, AUC0-tlast, %AUC, Cmax, tmax, t1/2, λz, CL, Vss, Vz, MRT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunogenicity of GNbAC1</measure>
    <time_frame>64 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>GNbAC1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GNbAC1 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose intravenous (IV) GNbAC1 placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GNbAC1</intervention_name>
    <description>Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg</description>
    <arm_group_label>GNbAC1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GNbAC1 placebo</intervention_name>
    <description>Single dose intravenous (IV) GNbAC1 placebo</description>
    <arm_group_label>GNbAC1 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male healthy subjects, 18-55 years of age and in good health as determined by past&#xD;
             medical history, physical examination, vital signs, electrocardiogram and laboratory&#xD;
             tests at Screening and confirmed at baseline.&#xD;
&#xD;
          -  Clinically acceptable for the purposes of the study sitting blood pressure and pulse&#xD;
             rate, i.e.: BP: 100 - 150 mm Hg systolic, 50 - 95 mm Hg diastolic and pulse rate: 45 -&#xD;
             100 bpm. Blood pressure and pulse will be measured after 3 minutes resting in a&#xD;
             sitting position.&#xD;
&#xD;
          -  Body mass index between 18.5 and 30.0 kg/m2 and body weight in the 50 - 95 kg range.&#xD;
&#xD;
          -  No need for regular concomitant medication&#xD;
&#xD;
          -  Subjects with partners of childbearing potential have to use adequate contraception&#xD;
             during, and for at least the four weeks after administration of study medication.&#xD;
             Adequate contraception is defined as usage by at least one of the partners of a&#xD;
             barrier method of contraception, together with usage by the female partner, commencing&#xD;
             at least three months prior to Screening, of a stable regimen of any form of hormonal&#xD;
             contraception or an intra-uterine device. Use of abstinence alone is not considered&#xD;
             adequate. Use of a barrier method alone is considered adequate only if the subject was&#xD;
             vasectomized at least six months prior to Screening.&#xD;
&#xD;
          -  Ability to communicate well with the investigator and comply with the requirements of&#xD;
             the entire study.&#xD;
&#xD;
          -  The subject has given written consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of serious adverse reactions or hypersensitivity to any drug.&#xD;
&#xD;
          -  Presence or history of any allergy requiring acute or chronic treatment (seasonal&#xD;
             allergic rhinitis which requires no treatment may be tolerated).&#xD;
&#xD;
          -  Abnormal physical findings of clinical significance at the Screening or baseline&#xD;
             examination which would interfere with the objectives of the study.&#xD;
&#xD;
          -  Need of any prescription medication within 30 days prior to the administration of the&#xD;
             drug and/or nonprescription medication within 7 days prior to the administration of&#xD;
             the drug or anticipated need for any concomitant medication during the study.&#xD;
&#xD;
          -  Participation in a clinical trial during the previous 4 weeks, i.e. from completion of&#xD;
             the previous trial to the planned first administration of the current trial.&#xD;
&#xD;
          -  Loss of 500 mL blood or more during the 3 month period before the screening visit of&#xD;
             the study, e.g. as a donor.&#xD;
&#xD;
          -  Existence of any surgical or medical condition which might relevantly interfere with&#xD;
             the subject safety, the distribution, metabolism or excretion of the drug or the study&#xD;
             assessments, i.e. impaired renal or hepatic function, diabetes mellitus,&#xD;
             cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhea&#xD;
             or conditions associated with total or partial obstruction of the urinary tract.&#xD;
&#xD;
          -  Symptoms of a significant (upon Investigator's medical judgment) somatic or mental&#xD;
             illness in the two week period preceding drug administration.&#xD;
&#xD;
          -  History or clinical evidence of significant cardiovascular, respiratory, renal,&#xD;
             hepatic,gastrointestinal, hematological, neurologic or other disease.&#xD;
&#xD;
          -  History of hepatitis B and / or C and / or positive serology results which indicate&#xD;
             the presence of hepatitis B and / or C.&#xD;
&#xD;
          -  Positive results from the HIV serology.&#xD;
&#xD;
          -  Positive for MSRV env by RNA PCR&#xD;
&#xD;
          -  Clinically significant abnormal laboratory values (as determined by the Principal&#xD;
             Investigator in consultation with the sponsor) at the Screening or baseline&#xD;
             evaluation.&#xD;
&#xD;
          -  History of serious mental disorders.&#xD;
&#xD;
          -  History of alcohol or drug abuse in the last 3 years.&#xD;
&#xD;
          -  Heavy smokers, i.e. more than 10 cigarettes per day and/or unwillingness to refrain&#xD;
             from smoking during the entire in-house period.&#xD;
&#xD;
          -  Positive results of the drug Screening.&#xD;
&#xD;
          -  Need for a vaccination from Screening to End of Study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Kamtchoua, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit AG</affiliation>
  </overall_official>
  <results_reference>
    <citation>Curtin F, Lang AB, Perron H, Laumonier M, Vidal V, Porchet HC, Hartung HP. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study. Clin Ther. 2012 Dec;34(12):2268-78. doi: 10.1016/j.clinthera.2012.11.006. Epub 2012 Nov 29.</citation>
    <PMID>23200102</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>September 27, 2012</study_first_submitted>
  <study_first_submitted_qc>October 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2012</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>GNbAC1</keyword>
  <keyword>Monoclonal antibody</keyword>
  <keyword>Multiple Sclerosis Associated Retrovirus (MSRV)</keyword>
  <keyword>Temelimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01699555
org study id: GNC-001
nct id: NCT01699555
lead sponsor: 
has dmc: No
The purpose of this study is to assess the safety and tolerability of single ascending doses
      of GNbAC1 in healthy male subjects.
Scientific research has shown that the expression of genes of a virus which is integrated in
      the Human genetic material, the Multiple Sclerosis associated RetroVirus (MSRV) could play a
      critical role in the causation of multiple sclerosis. GNbAC1 is an experimental medication,
      which neutralizes (i.e. inactivates) a protein of MSRV that might contribute to the
      development or deterioration of multiple sclerosis.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Triple (Participant, Investigator, Outcomes Assessor)
measure: number of reported adverse events for healthy male subjects receiving single ascending doses of GNbAC1.
time frame: 64 days
description: the number of adverse events along with the results of physical examinations, ECG and clinical laboratory tests will be used to determine the safety profile of GNbAC1.
measure: pharmacokinetics (PK) characteristics following administration of single ascending doses of GNbAC1 in healthy male subjects
time frame: 64 days
description: the following parameters will be determined: serum concentrations of GNbAC1 and the derived PK parameters AUC0-inf, AUC0-tlast, %AUC, Cmax, tmax, t1/2, λz, CL, Vss, Vz, MRT.
measure: immunogenicity of GNbAC1
time frame: 64 days
arm group label: GNbAC1
arm group type: Experimental
description: Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
arm group label: GNbAC1 placebo
arm group type: Placebo Comparator
description: Single dose intravenous (IV) GNbAC1 placebo
intervention type: Biological
intervention name: GNbAC1
description: Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
arm group label: GNbAC1
intervention type: Biological
intervention name: GNbAC1 placebo
description: Single dose intravenous (IV) GNbAC1 placebo
arm group label: GNbAC1 placebo
criteria: 
gender: Male
minimum age: 18 Years
maximum age: 55 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Thierry Kamtchoua, M.D
role: Principal Investigator
affiliation: Covance Clinical Research Unit AG
citation: Curtin F, Lang AB, Perron H, Laumonier M, Vidal V, Porchet HC, Hartung HP. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study. Clin Ther. 2012 Dec;34(12):2268-78. doi: 10.1016/j.clinthera.2012.11.006. Epub 2012 Nov 29.
PMID: 23200102
responsible party type: Sponsor
mesh term: Multiple Sclerosis
mesh term: Sclerosis